A Phase I/II Study of Azacitidine in Haploidentical Donor Hematopoietic Cell Transplantation
Active, no longer recruiting
Phase of Trial: Phase I/II
Latest Information Update: 22 Nov 2017
At a glance
- Drugs Azacitidine (Primary) ; Cyclophosphamide (Primary) ; Fludarabine (Primary) ; Granulocyte colony-stimulating factors (Primary) ; Melphalan (Primary)
- Indications Acute lymphoblastic leukaemia; Acute myeloid leukaemia; Myelodysplastic syndromes
- Focus Adverse reactions
- 03 Oct 2017 Planned End Date changed from 31 Jul 2021 to 14 Oct 2020.
- 03 Oct 2017 Status changed from recruiting to active, no longer recruiting.
- 14 Feb 2017 Planned End Date changed from 31 Jul 2020 to 31 Jul 2021.